CLL
From the Journals
CLL: Venetoclax combos top first-line chemoimmunotherapy
A triple-therapy combination yielded the best outcomes, but it should still be considered investigational.
From the Journals
Number of cancer survivors with functional limitations doubled in 20 years
The 70% prevalence of functional limitation among survivors in 2018 is nearly twice that of the general population.
From the Journals
CLL: Black patients die sooner than White patients
Researchers suspect that multiple factors – including biology – could be behind the racial disparity found in this large study.
Commentary
Some decisions aren’t right or wrong; they’re just devastating
One might wonder: Why is it so hard to do the right thing? Ask any clinician and I think you will hear the same answer: because we do not have the...
Conference Coverage
Frontline CLL treatment: Avoiding adverse events
Single-agent frontline therapy helps patients with CLL live longer, but those at high risk of relapse may benefit from multiagent treatment.
Conference Coverage
Relapsed CLL: New approaches prolong survival
Venetoclax, with a second-generation generation Bruton’s tyrosine kinase inhibitor, can lead patients with relapsed CLL back to remission.
Latest News
Cancer, heart disease vaccines may be ready by 2030, Moderna says
The announcement is yet another sign of what many are calling “the golden age” of vaccine development.
From the Journals
Price of CLL Rx rises, despite competition
The cost of ibrutinib keeps going up, in spite of newer treatment options.
From the Journals
MRD: Powerful metric for CLL research
New study showed how leukemia specialists can harness measurable residual disease to gauge the efficacy of novel treatment options.
From the Journals
B-cell cancers: Sparse insight into preventing infections
Doctors treating CLL and other B-cell cancers are blindsided by a lack of research into acquired hypogammaglobulinemia prophylactics.
From the Journals
CLL and surgery are more compatible than ever
As patients fare better with targeted therapy, physicians say they can tolerate more procedures.